Retinal Disorder Treatment Market Size, Share & Trends Analysis Report By Type (Macular Degeneration, Diabetic Retinopathy), By Dosage Form, By Distribution Channel, By Product Type- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global Retinal Disorder Treatment market size was exhibited at USD 12.59 billion in 2022 and is projected to hit around USD 31.2 billion by 2032, growing at a CAGR of 9.5% during the forecast period 2023 to 2032.

Key Pointers:

• By type, the macular degeneration segment held the largest market share in 2022, which is attributable to its high prevalence, rising awareness about the disease, and promising pipeline products
• Eye drops dosage form segment is projected to grow at the fastest rate over the forecast period due to its high adoption and ease of use
• Hospital pharmacies held a dominant share of the distribution channel segment in 2022 due to the ease of access and availability of patient records
• North America dominated the global market in 2022 and is expected to grow considerably in the future, owing to the rising prevalence of retinal disorders and the increasing consumer awareness about retinal disorders

Retinal Disorder Treatment Market Report Scope

Growth in the market is fueled by the increasing prevalence of retinal disorders around the world and the unmet need for affordable and efficient treatments. Furthermore, improved funding by regulatory bodies for R&D associated with ocular disorders is expected to further drive market growth.

Retinal diseases are one of the leading causes of visual impairment among the global population. According to WHO, in 2022, a near or distant vision impairment affects at least 2.2 billion people worldwide. Nearly half of these cases, or around 1 billion, involved vision impairments that either could have been avoided or are still unaddressed. Factors such as changing lifestyles, increased life expectancy, and escalating prevalence of systemic diseases like hypertension and diabetes mellitus are the most common causes of retinal disorders. This demonstrates an unmet need among retinal disorder patients for treatment of the condition.

The rising geriatric population is acting as a driver for the market; age-related macular degeneration (AMD) is one of the leading causes of vision loss in people aged over 65 years. AMD is characterized by the degeneration of an area of the retina known as the macula, which is responsible for central vision. The growing elderly population is expected to create a wider patient pool for the treatment of AMD. For instance, according to a WHO report in 2021, by 2030, 1 in every 6 people in the world will be aged 60 years or over. Furthermore, over this period of time, the population aged over 60 years is expected to increase from 1 billion in 2020 to 1.4 billion.

The high cost associated with retinal disorder treatment poses a threat to the growth of the market. However, increasing efforts from key players operating in the market for developing new products for the enhancement of their product pipeline is expected to drive the market. For instance, in January 2022, Genentech’s Vabysmo was approved by the FDA, the first-in-class bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. The launch of novel products is expected to propel market growth.

North America dominated the global market with a revenue share of 38.9% in 2022 and is anticipated to grow at a significant rate, driven by factors such as the growing geriatric population, the increasing launch of novel products, and enhanced awareness levels about eye conditions. As per BrightFocus Foundation, in 2019, 11 million people were suffering from AMD in the U.S., and the number is projected to double by 2050. With rising cases of the condition, there is a rising need for the development of effective therapeutics, which enable key players to launch newer drugs. For instance, in December 2022, Olix Pharmaceuticals completed the registration for phase 1 clinical trials of OLX301A for wet and dry muscular degeneration treatment in the U.S.

Asia Pacific is estimated to be the fastest-growing market during the forecast period owing to the increasing awareness among the population about early diagnosis & treatment, rising disposable income, and availability of effective and efficient treatment methods. For instance, as of 2021, India has 74 million diabetics, while 12.5 million of these suffer from diabetic retinopathy of some form. Thus, the presence of a high number of target patients is creating opportunities in the region.

Some of the prominent players in the Retinal Disorder Treatment Market include:

• Santen Pharmaceutical Co., Ltd.
• Regeneron Pharmaceuticals Inc.
• Graybug Vision, Inc.
• Shire (Takeda Pharmaceutical Company Limited)
• Bayer AG
• Allergan plc. (AbbVie Inc.)
• Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
• Acucela Inc.
• Pfizer, Inc.
• Kubota Pharmaceutical Holdings Co., Ltd.,

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Retinal Disorder Treatment market.

By Type 

• Macular Degeneration
  • Dry Macular Degeneration
  • Wet Macular Degeneration
• Diabetic Retinopathy
• Others

By Dosage Form 

• Gels
• Eye Solutions
• Capsules & Tablets
• Eye Drops
• Ointments

By Distribution Channel 

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)